Improving the Management of Ulcerative Colitis – Issue 2 – Page 5

NSCLC iNewsletter Series - Issue 1
 
<< Previous Page 1 2345
 

REFERENCES

1. Velayos FS, Sandborn WJ. Positioning biologic therapy for Crohn’s disease and ulcerative colitis. Curr Gastroenterol Rep. 2007;9(6):521-527.

Abstract


2. Jess T, Riis L, Vind I, et al. Changes in clinical characteristics, course, and prognosis of inflammatory bowel disease during the last 5 decades: a population-based study from Copenhagen, Denmark. Inflamm Bowel Dis. 2007;(4):481-489.

Abstract


3. Faubion WA, Loftus EV, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology. 2001;121(2):255-260.

Abstract


4. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353(23):2462-2476.

Abstract


5. Reinisch W, Sandborn WJ, Hommes DW, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut. 2011;60(6):780-787.

Abstract


6. Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2013 Jun 13. pii: S0016-5085(13)00886-X. doi: 10.1053/j.gastro.2013.06.010. [Epub ahead of print]

Abstract


7. Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012;142(2):257-265.

Abstract


8. Sandborn WJ. Step-up versus top-down therapy in the treatment of ulcerative colitis. Gastroenterol Hepatol (N Y). 2007;3(1):16-17.

Abstract


9. Tung J, Loftus EV, Freese DK, et al. A population-based study of the frequency of corticosteroid resistance and dependence in pediatric patients with Crohn’s disease and ulcerative colitis. Inflamm Bowel Dis. 2006;12(12):1093-1100.

Abstract


10. D’Haens G, Baert F, Van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trial. Lancet. 2008;371(9613):660-667.

Abstract


11. Sandborn WJ. Initial combination therapy in early Crohn’s disease. Lancet. 2008;371(9613):635-636.

Abstract


12. Colombel JF, Rutgeerts P, Reinisch W, et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology. 2011;141(4):1194-1201.

Abstract


13. Melmed GY. Vaccination strategies for patients with inflammatory bowel disease on immunomodulators and biologics. Inflamm Bowel Dis. 2009;15(9):1410-1416.

Abstract


14. Rahier J-F, Ben-Horin S, Chowers Y, et al. European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis. 2009;3(2):47-91.

Abstract


15. D’Haens GR, Panaccione R, Higgins PD, et al. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn’s and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol. 2011;106(2):199-212.

Abstract


16. Kane S, Khatibi B, Reddy D. Higher incidence of abnormal Pap smears in women with inflammatory bowel disease. Am J Gastroenterol. 2008;103(3):631-636.

Abstract


17. Afif W, Loftus EV. Safety profile of IBD therapeutics: infectious risks. Med Clin North Am. 2010;94(1):115-133.

Abstract


18. van Assche G, Lewis JD, Lichtenstein GR, et al. The London position statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn’s and Colitis Organisation: safety. Am J Gastroenterol. 2011;106(9):1594-1602.

Abstract


19. Ordás I, Eckmann L, Talamini M, Baumgart DC, Sandborn WJ. Ulcerative colitis. Lancet. 2012;380(9853):1606-1619.

Abstract


20. van Assche G. Optimizing biologic therapy for treatment of inflammatory bowel disease. Gastroenterol Hepatol (N Y). 2013;9(7):462-464.

Abstract


21. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Eng J Med. 2005;353(23):2462-2476.

Abstract


22. Reinisch W, Sandborn WJ, Rutgeerts P, et al. Long-term infliximab maintenance therapy for ulcerative colitis: the ACT-1 and -2 extension studies. Inflamm Bowel Dis. 2012;18(2):201-211.

Abstract


23. Sandborn WJ, Colombel JF, D’Haens G, et al. One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2. Aliment Pharmacol Ther. 2013;37(2):204-213.

Abstract


24. Reinisch W, Sandborn WJ, Panaccione R, et al. 52-week efficacy of adalimumab in patients with moderately to severely active ulcerative colitis who failed corticosteroids and/or immunosuppressants. Inflamm Bowel Dis. 2013;19(8):1700-1709.

Abstract


25. Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate to severe ulcerative colitis. Gastroenterology. 2013, Jun 2; pii: S0016-5085(13)00846-9. doi: 10.1053/j.gastro.2013.05.048. [Epub ahead of print].

Abstract


26. Devlin SM, Cheifetz AS, Siegel CA, BRIDGe group. Patient-specific approach to combination versus monotherapy with the use of antitumor necrosis factor α agents for inflammatory bowel disease. Gastroenterol Clin North Am. 2012;41(2):411-428.

Abstract


27. Ferrante M, D’Haens G, Rutgeerts P, Vermeire S, van Assche G. Optimizing biologic therapies for inflammatory bowel disease (ulcerative colitis and Crohn’s disease). Curr Gastroenterol Rep. 2009;11(6):504-508.

Abstract


28. Danese S, Colombel JF, Peyrin-Biroulet L, Rutgeerts P, Reinisch W. Review article: the role of anti-TNF in the management of ulcerative colitis‒past, present and future. Aliment Pharmacol Ther. 2013;37(9):855-866.

Abstract


29. Ordás I, Feagan BG, Sandborn WJ. Therapeutic drug monitoring of tumor necrosis factor antagonists in inflammatory bowel disease. Clin Gastroenterol Hepatol. 2012;10(10):1079-1087.

Abstract


30. Seow CH, Newman A, Irwin SP, Steinhart AH, Silverberg MS, Greenberg GR. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut. 2010;59(1):49-54.

Abstract


31. Langholz E, Munkholm P, Davidsen M, Binder V. Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology. 1994;107(1):3-11.

Abstract


32. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002;359(9317):1541-1549.

Abstract


33. Taxonera C, Estelles J, Fernández-Blanco I, Merino, et al. Adalimumab induction and maintenance therapy for patients with ulcerative colitis previously treated with infliximab. Aliment Pharmacol Ther. 2011;33(3):340-348.

Abstract


34. Colombel J-F, Feagan BG, Sandborn WJ, van Assche G, Robinson AM. Therapeutic drug monitoring of biologics for inflammatory bowel disease. Inflamm Bowel Dis. 2012;18(2):349-358.

Abstract


35. Ordás I, Mould DR, Feagan BG, Sandborn WJ. Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms. Clin Pharmacol Ther. 2012;91(4):635-646.

Abstract


36. Colombel JF, Feagan BG, Sandborn WJ, van Assche G, Robinson AM. Therapeutic drug monitoring of biologics for inflammatory bowel disease. Inflamm Bowel Dis. 2012;18(2):349-358.

Abstract


37. Oussalah A, Evesque L, Laharie D, et al. A multicenter experience with infliximab for ulcerative colitis: outcomes and predictors of response, optimization, colectomy, and hospitalization. Am J Gastroenterol. 2010;105(12):2617-2625.

Abstract


38. Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med. 2007;146(12):829-838.

Abstract


39. Afif W, Loftus EV, Faubion WA, et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol. 2010;105(5):1133-1139.

Abstract


40. Lichtenstein GR. Comprehensive review: antitumor necrosis factor agents in inflammatory bowel disease and factors implicated in treatment response. Therap Adv Gastroenterol. 2013;6(4):269-293.

Abstract


41. Maser EA, Villela R, Silverberg MS, Greenberg GR. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn’s disease. Clin Gastroenterol Hepatol. 2006;4(10):1248-1254.

Abstract


42. Reinisch W, Feagan BG, Rutgeerts PJ, et al. 566 Infliximab concentration and clinical outcome in patients with ulcerative colitis. Gastroenterology. 2012;142(5):S-114.

Abstract


43. Siegel CA, Finlayson SR, Sands BE, Tosteson AN. Adverse events do not outweigh benefits of combination therapy for Crohn’s disease in a decision analytic model. Clin Gastroenterol Hepatol. 2012;10(1):46-51.

Abstract


44. Siegel CA. Making therapeutic decisions in inflammatory bowel disease: the role of patients. Curr Opin Gastroenterol. 2009;25(4):334-338.

Abstract


45. Siegel CA. Shared decision making in inflammatory bowel disease: helping patients understand the tradeoffs between treatment options. Gut. 2012;61(3):459-465.

Abstract


46. Siegel CA. Review article: explaining risks of inflammatory bowel disease therapy to patients. Aliment Pharmacol Ther. 2011;33(1):23-32.

Abstract

1 2345

 

CMEcorner is an educational service of MCM Education • 54 Friends Lane, Suite 125 • Newtown, PA 18940



VN:F [1.9.22_1171]
Rating: 5.0/5 (1 vote cast)
Improving the Management of Ulcerative Colitis – Issue 2 – Page 5, 5.0 out of 5 based on 1 rating